Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1994 1
1997 6
1998 23
1999 57
2000 120
2001 170
2002 310
2003 379
2004 478
2005 615
2006 781
2007 954
2008 1143
2009 1274
2010 1416
2011 1555
2012 1700
2013 1774
2014 1940
2015 1994
2016 1906
2017 2003
2018 1955
2019 1982
2020 2315
2021 2617
2022 2350
2023 2182
2024 732

Text availability

Article attribute

Article type

Publication date

Search Results

30,302 results

Results by year

Filters applied: . Clear all
Page 1
Rituximab treatment of ANCA-associated vasculitis.
Raffray L, Guillevin L. Raffray L, et al. Expert Opin Biol Ther. 2020 Aug;20(8):899-910. doi: 10.1080/14712598.2020.1748597. Epub 2020 May 5. Expert Opin Biol Ther. 2020. PMID: 32293192 Review.
INTRODUCTION: Rituximab, an anti-B-cell biological therapy, has been investigated in several clinical trials on antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs). AREAS COVERED: In this paper, the clinical trials and open-label studies on …
INTRODUCTION: Rituximab, an anti-B-cell biological therapy, has been investigated in several clinical trials on antineutrophil …
Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?
Lucchini E, Zaja F, Bussel J. Lucchini E, et al. Haematologica. 2019 Jun;104(6):1124-1135. doi: 10.3324/haematol.2019.218883. Epub 2019 May 24. Haematologica. 2019. PMID: 31126963 Free PMC article. Review.
The use of rituximab for the treatment of immune thrombocytopenia was greeted enthusiastically: it led to up to 60% response rates, making it, nearly 20 years ago, the main alternative to splenectomy, with far fewer side effects. ...In this review we examine the his …
The use of rituximab for the treatment of immune thrombocytopenia was greeted enthusiastically: it led to up to 60% response r …
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Maloney DG, Crotta A, Montheard S, Previtali A, Stepan L, Ogasawara K, Mack T, Abramson JS; TRANSFORM Investigators. Kamdar M, et al. Lancet. 2022 Jun 18;399(10343):2294-2308. doi: 10.1016/S0140-6736(22)00662-6. Lancet. 2022. PMID: 35717989 Clinical Trial.
In this Article, we report a prespecified interim analysis of liso-cel versus standard of care as second-line treatment for primary refractory or early relapsed (within 12 months after response to initial therapy) LBCL. ...No new liso-cel safety concerns were identi …
In this Article, we report a prespecified interim analysis of liso-cel versus standard of care as second-line treatment for primary r …
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience.
Salles G, Barrett M, Foà R, Maurer J, O'Brien S, Valente N, Wenger M, Maloney DG. Salles G, et al. Adv Ther. 2017 Oct;34(10):2232-2273. doi: 10.1007/s12325-017-0612-x. Epub 2017 Oct 5. Adv Ther. 2017. PMID: 28983798 Free PMC article. Review.
Since its first approval 20 years ago, intravenously administered rituximab has revolutionized the treatment of B-cell malignancies and has become a standard component of care for follicular lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia, and …
Since its first approval 20 years ago, intravenously administered rituximab has revolutionized the treatment of B-cell maligna …
Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial.
Piehl F, Eriksson-Dufva A, Budzianowska A, Feresiadou A, Hansson W, Hietala MA, Håkansson I, Johansson R, Jons D, Kmezic I, Lindberg C, Lindh J, Lundin F, Nygren I, Punga AR, Press R, Samuelsson K, Sundström P, Wickberg O, Brauner S, Frisell T. Piehl F, et al. JAMA Neurol. 2022 Nov 1;79(11):1105-1112. doi: 10.1001/jamaneurol.2022.2887. JAMA Neurol. 2022. PMID: 36121672 Free PMC article.
INTERVENTIONS: Participants were randomized 1:1 without stratification to a single intravenous infusion of 500 mg of rituximab or matching placebo. MAIN OUTCOMES AND MEASURES: Minimal disease manifestations at 16 weeks defined as a QMG score of 4 or less with prednisolone, …
INTERVENTIONS: Participants were randomized 1:1 without stratification to a single intravenous infusion of 500 mg of rituximab or mat …
Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders.
Kaegi C, Wuest B, Schreiner J, Steiner UC, Vultaggio A, Matucci A, Crowley C, Boyman O. Kaegi C, et al. Front Immunol. 2019 Sep 6;10:1990. doi: 10.3389/fimmu.2019.01990. eCollection 2019. Front Immunol. 2019. PMID: 31555262 Free PMC article.
This systematic review is the first of a series of articles assessing the safety and efficacy of B cell-targeting biologics for the treatment of immune-mediated diseases. Objective: To evaluate rituximab's safety and efficacy for the treatment of immun …
This systematic review is the first of a series of articles assessing the safety and efficacy of B cell-targeting biologics for the treat …
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial.
Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, Caillot F, Golinski ML, Labeille B, Picard-Dahan C, Paul C, Richard MA, Bouaziz JD, Duvert-Lehembre S, Bernard P, Caux F, Alexandre M, Ingen-Housz-Oro S, Vabres P, Delaporte E, Quereux G, Dupuy A, Debarbieux S, Avenel-Audran M, D'Incan M, Bedane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Vermeulin T, Benichou J, Musette P; French study group on autoimmune bullous skin diseases. Joly P, et al. Lancet. 2017 May 20;389(10083):2031-2040. doi: 10.1016/S0140-6736(17)30070-3. Epub 2017 Mar 22. Lancet. 2017. PMID: 28342637 Clinical Trial.
BACKGROUND: High doses of corticosteroids are considered the standard treatment for pemphigus. Because long-term corticosteroid treatment can cause severe and even life-threatening side-effects in patients with this disease, we assessed whether first-line use of …
BACKGROUND: High doses of corticosteroids are considered the standard treatment for pemphigus. Because long-term corticosteroid tr …
Clinical and biological activity of rituximab in the treatment of pemphigus.
Bohelay G, Caux F, Musette P. Bohelay G, et al. Immunotherapy. 2021 Jan;13(1):35-53. doi: 10.2217/imt-2020-0189. Epub 2020 Oct 12. Immunotherapy. 2021. PMID: 33045883 Review.
Major advances were obtained using whole B-cell depleting therapies including anti-CD20 antibodies in refractory pemphigus patients that lead to rituximab approval in pemphigus patients in EU and USA. This review summarizes the data supporting the efficacy of rituximab …
Major advances were obtained using whole B-cell depleting therapies including anti-CD20 antibodies in refractory pemphigus patients that lea …
Rituximab treatment in seronegative autoimmune autonomic neuropathy and autoimmune autonomic ganglionopathy: Case-report and literature review.
Bouxin M, Schvartz B, Mestrallet S, Debrumetz A, Hentzien M, Tabary T, Cohen R, Nicolas G, Bani-Sadr F. Bouxin M, et al. J Neuroimmunol. 2019 Jan 15;326:28-32. doi: 10.1016/j.jneuroim.2018.11.009. Epub 2018 Nov 14. J Neuroimmunol. 2019. PMID: 30468952 Review.
We also provide a review of case-reports reporting rituximab treatment for both SAAN and AAG. METHODS: To identify articles reporting SAAN and AAG treatment with rituximab, we searched the PubMed database using the terms "autoimmune autonomic gangliono …
We also provide a review of case-reports reporting rituximab treatment for both SAAN and AAG. METHODS: To identify articles re …
Rituximab for the treatment of acute exacerbation of interstitial lung disease associated with connective tissue disease.
León Román F, Pintado-Cort B, García-Casado D, Muñiz-González F, López García-Asenjo JA, Díaz-Rodríguez C, Montoro-López MN, Loucel-Bellino M, Recio-Moreno B, Rebollo-Garrido S, Martínez-Hernández Y, Cusacovich I. León Román F, et al. RMD Open. 2023 Sep;9(3):e003479. doi: 10.1136/rmdopen-2023-003479. RMD Open. 2023. PMID: 37673443 Free PMC article.
BACKGROUND: Acute exacerbation of interstitial lung disease (AE-ILD) is a severe complication with a poor prognosis. No clinical trials have supported the use of rituximab in AE-ILD associated with connective tissue disease. METHODS: We present a series of four cases in wh …
BACKGROUND: Acute exacerbation of interstitial lung disease (AE-ILD) is a severe complication with a poor prognosis. No clinical trials have …
30,302 results
You have reached the last available page of results. Please see the User Guide for more information.

Searches related to "rituximab treatment"